Subscribe to Journal
Get full journal access for 1 year
only $102.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Talati C, Isenalumhe LL, Shams SR, Kuykendall AT, Chavez JC, Shah BD. et al. Outcomes of blast phase chronic myeloid leukemia (BP-CML) in the tyrosine kinase inhibitor (TKI) era. J Clin Oncol. 2017;35 Suppl 15:e18546 .
Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-Year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333–40.
Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–54.
Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987;83:445–54.
Chen X, Rutledge JC, Wu D, Fang M, Opheim KE, Xu M. Chronic myelogenous leukemia presenting in blast phase with nodal, bilineal myeloid sarcoma and T-lymphoblastic lymphoma in a child. Pediatr Dev Pathol. 2013;16:91–6.
Gao X, Li J, Wang L, Lin J, Jin H, Xu Y, et al. Bilineal extramedullary blast crisis as an initial presentation of chronic myeloid leukemia: a case report and literature review. Am J Case Rep. 2016;17:793–8.
Akashi K, Mizuno S, Harada M, Kimura N, Kinjyo M, Shibuya T, et al. T lymphoid/myeloid bilineal crisis in chronic myelogenous leukemia. Exp Hematol. 1993;21:743–8.
Ruiz S, Chen YH. Acute myeloid leukemia with coexistence of t(9;22) and inv(16). Blood. 2018;131:1263.
Han E, Lee H, Kim M, Kim Y, Han K, Lee SE, et al. Characteristics of hematologic malignancies with coexisting t(9;22) and inv(16) chromosomal abnormalities. Blood Res. 2014;49:22–8.
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48.
Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med. 2019;11:eaau5907.
Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20:1479–84.
Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–60.
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–38.
Marinelli Busilacchi E, Costantini A, Viola N, Costantini B, Olivieri J, Butini L, et al. Immunomodulatory effects of tyrosine kinase inhibitor in vitro and in vivo study. Biol Blood Marrow Transplant. 2018;24:267–75.
The authors thank the patient and family, as well as the MGH nurses, advanced practitioners, research, and support staff. This retrospective analysis was approved by the Dana Farber/Harvard Cancer Center Institutional Review Board.
Conflict of interest
VV, KSC, MO, PDC, VN, PCA, MKB, JEF, JM, HH, CH, SM, and AMB, have no interests to disclose. ATF does scientific consulting for Celgene/BMS, Novartis, Agios, Astellas, Pfizer, Takeda, Amgen, Daiichi Sankyo, Kite, Trovagene, Forty-Seven, NewLink Genetics, and Abbvie, and receives research funding from Celgene and Abbvie. MF does scientific consulting for Novartis, Gilead, Celgene, Arcellx and is funded by the NIH K12CA087723. TG receives research support from Janssen and Calico. GH does scientific consulting for Incyte, Agios, Celgene, BMS, and Jazz as well as receives research support from Bayer, Incyte, Merck, Constellation and research grants in the form of NIH K12 CA087723 Paul Calabresi Award, ASH-AMFDP, and Sanchez Ferguson Research Award.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Venkataraman, V., Casey, K.S., Onozato, M. et al. Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. Leukemia (2020). https://doi.org/10.1038/s41375-020-0983-x